Sandoz Group AG (Sandoz Group AG) EBITDA Margin % : 8.59% (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is Sandoz Group AG EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Sandoz Group AG's EBITDA for the three months ended in Dec. 2023 was $857 Mil. Sandoz Group AG's Revenue for the three months ended in Dec. 2023 was $9,979 Mil. Therefore, Sandoz Group AG's EBITDA margin for the quarter that ended in Dec. 2023 was 8.59%.

Sandoz Group AG EBITDA Margin % Historical Data

The historical data trend for Sandoz Group AG's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sandoz Group AG EBITDA Margin % Chart

Sandoz Group AG Annual Data

Trend

Dec22

Dec23

EBITDA Margin %

18.09

8.59

Sandoz Group AG Quarterly Data
	Dec22	Dec23
EBITDA Margin %	18.09	8.59

Competitive Comparison of Sandoz Group AG's EBITDA Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Sandoz Group AG's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sandoz Group AG's EBITDA Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sandoz Group AG's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Sandoz Group AG's EBITDA Margin % falls into.

Sandoz Group AG EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Sandoz Group AG's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	857	/	9979
	=	8.59 %

Sandoz Group AG's EBITDA Margin % for the quarter that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	857	/	9979
	=	8.59 %

Sandoz Group AG (OTCPK:SDZNY) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Sandoz Group AG EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Sandoz Group AG's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Sandoz Group AG (Sandoz Group AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sandoz Group AG (OTCPK:SDZNY) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

SDZXF:USA SDZz:UK D8Y0:Germany SDZ:Switzerland

Address

Forum 1, Novartis Campus, Basel, CHE, CH-4056

Website

https://www.sandoz.com

Sandoz is one of the largest generic pharmaceutical manufacturers in the world, generating over $9 billion annually from off-patent drugs. Once part of Novartis, Sandoz spun off and went public in October 2023. Generics, including small molecules and complex injectables, make up roughly 75% of Sandoz's total sales, and the firm has a significant presence in Europe, the United States, and other key international markets. Sandoz generates its remaining sales from biosimilars and is among leaders in the space. Sandoz launched Europe's first biosimilar, Omnitrope, in 2006 as well as U.S.'s first biosimilar, Zarxio, in 2015. It currently has eight commercialized biosimilars in a number of markets and has over 20 assets in pipeline.

Sandoz Group AG (Sandoz Group AG) Headlines

From GuruFocus

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024

Q3 2023 Sandoz Group AG Earnings Call Transcript

By GuruFocus Research • 02-14-2024